SKINMEDIUM SIGNALFINANCIAL10-K

SKIN showed substantial improvement in operating losses and net losses while implementing balance sheet restructuring that reduced total assets by 27%.

The company appears to be executing a turnaround strategy, with operating losses narrowing substantially from prior year levels, suggesting improved operational efficiency. However, the significant reduction in total assets and current assets indicates either strategic downsizing or potential liquidity management, which investors should monitor closely.

Comparing 2026-03-12 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

SKIN demonstrated meaningful improvement in profitability metrics, with both operating losses and net losses narrowing substantially year-over-year. The company reduced its balance sheet footprint significantly, with total assets declining 27% and current assets falling 35%, while total liabilities decreased 31% and inventory dropped 31%. Despite the asset reduction, stockholders' equity grew 18%, suggesting the company successfully deleveraged while improving its capital structure and moving toward operational breakeven.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+69.3%
-$67.8M→-$20.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+67.3%
-$29.1M→-$9.5M

Net income grew 67.3% — bottom-line growth signals improving overall business health.

Capital Expenditure
Cash Flow
-59.9%
$756K→$303K

Capex reduced 59.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
-35.1%
$477.1M→$309.5M

Current assets declined 35.1% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-30.8%
$633.9M→$438.7M

Liabilities reduced 30.8% — deleveraging improves balance sheet strength and financial flexibility.

Inventory
Balance Sheet
-30.5%
$69.1M→$48.0M

Inventory drawn down 30.5% — strong sell-through or deliberate destocking; watch for supply constraints.

Total Assets
Balance Sheet
-27.1%
$685.7M→$499.8M

Total assets contracted 27.1% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
-21.4%
$27.6M→$21.7M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
+17.9%
$51.8M→$61.1M

Equity base grew 17.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
-10.6%
$6.3M→$5.6M

R&D spending cut 10.6% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-12
ADDED
As of March 9, 2026, there were 127,773,050 shares of Class A Common Stock, par value $0.0001 per share issued and outstanding.
All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding the financial position, business strategy, and the plans and objectives of management for our future operations, are forward-looking statements.
When used in this Annual Report on Form 10-K, the words anticipates, believes, estimates, expects, forecasts, intends, plans, may, will, potential, projects, predicts, continue, scheduled or should, or, in each case, their negative or other variations or comparable terminology are intended to identify forward-looking statements.
Our new product introductions may not be, and at times in the past have not been, as successful as we anticipate.
We currently face, and may continue to face, product liability claims, which could result in unexpected costs and damage our reputation.
We are currently, and may continue to be, subject to securities litigation, which is expensive to defend and could divert management s attention.
Company Overview The Beauty Health Company (the Company or we ) is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers.
Anchored by Hydrafacial, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp powered by Keravive, the Company combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide.
The treatment extends to the scalp through the Company s HydraScalp powered by Keravive treatment, which is designed to support the hair s natural growth by cleansing, exfoliating, and hydrating the scalp and hair follicles for a visibly improved appearance of healthier, thicker, fuller-looking hair.
SkinStylus is a pioneer in nano-channeling and microneedling where its products are designed to provide either a non-invasive (nano-channeling) or minimally-invasive (microneedling) skin treatment to individuals.
REMOVED
As of March 10, 2025, there were 125,245,176 shares of Class A Common Stock, par value $0.0001 per share issued and outstanding.
The words believes, estimates, anticipates, expects, intends, plans, may, will, potential, projects, predicts, continue, or should, or, in each case, their negative or other variations or comparable terminology.
Such statements include, but are not limited to, any statements that are not statements of current or historical facts.
Our new product introductions may not be as successful as we anticipate.
We have a history of net losses and may experience future losses.
Our workforce reductions may cause undesirable consequences and our results of operations may be harmed.
Our business could also be adversely affected by our inability to repay or refinance existing debt.
Climate change and governmental actions to reduce such change may disrupt our operations and/or reduce consumer demand for our products.
We may face product liability claims, which could result in unexpected costs and damage our reputation.
We may be subject to securities litigation, which is expensive to defend and could divert management s attention.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →